HealthWarehouse.com (HEWA) 10-K 30 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 27, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	HealthWarehouse.com, Inc.
Entity Central Index Key	754813
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$2,968,000
Entity Common Stock, Shares Outstanding		37,570,383
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash	$506,019	$67,744
Restricted cash	195,088
Accounts receivable, net	100,886	307,211
Inventories	144,236	277,300
Prepaid expenses and other current assets	60,202	59,143
Total current assets	1,006,431	711,398
Property and equipment, net	511,286	624,634
Web development costs, net	142,541	83,780
Total assets	1,660,258	1,419,812
Current liabilities:
Accounts payable - trade	2,542,938	3,310,000
Accounts payable - related parties	84,314	83,691
Accrued expenses and other current liabilities	680,506	621,052
Deferred revenue	7,009	95,792
Current portion of equipment lease payable	64,101	56,323
Notes payable, net of debt discount of $58,367 as of December 31, 2014	791,633
Note payable and other advances - related parties	73,095	78,095
Redeemable preferred stock - Series C; par value $0.001 per share; 10,000 designated Series C: 10,000 issued and outstanding as of December 31, 2014 and December 31, 2013 (aggregate liquidation preference of $1,000,000)	1,000,000	1,000,000
Total current liabilities	5,243,596	5,244,953
Long term liabilities:
Notes payable and other advances, net of debt discount of $269,998 as of December 31, 2013		430,002
Long term portion of equipment lease payable	46,143	109,964
Total long term liabilities	46,143	539,966
Total liabilities	5,289,739	5,784,919
Preferred stock - par value $0.001 per share; authorized 1,000,000 shares; issued and outstanding as of December 31, 2014 and December 31, 2013 as follows:
Convertible preferred stock - Series A - 200,000 shares designated Series A; 44,443 shares available to be issued; no shares issued and outstanding
Convertible preferred stock - Series B - 625,000 shares designated Series B; 451,879 and 422,315 shares issued and outstanding as of December 31, 2014 and December 31, 2013, respectively (aggregate liquidation preference of $4,569,175 and $4,270,257 as of December 31, 2014 and December 31, 2013, respectively)	452	422
Common stock - par value $0.001 per share; 100,000,000 shares authorized, 38,749,595 and 27,708,303 shares issued and 37,570,383 and 26,529,091 shares outstanding as of December 31, 2014 and December 31, 2013, respectively	38,751	27,708
Additional paid-in capital	29,966,039	27,166,147
Employee advances	-2,143	-9,001
Treasury stock, at cost, 1,179,212 shares as of December 31, 2014 and December 31, 2013	-3,419,715	-3,419,715
Accumulated deficit	-30,212,865	-28,130,668
Total stockholders' deficiency	-3,629,481	-4,365,107
Total liabilities and stockholders' deficiency	$1,660,258	$1,419,812

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current liabilities:
Current portion of notes payable, net of debt discount	$58,367
Redeemable preferred stock Series C, par value	0.001	0.001
Redeemable preferred stock Series C, shares designated	10,000	10,000
Redeemable preferred stock Series C, shares issued	10,000	10,000
Redeemable preferred stock Series C, shares outstanding	10,000	10,000
Redeemable preferred stock Series C, aggregate liquidation preference	1,000,000	1,000,000
Long term liabilities:
Noncurrent portion of notes payable, net of debt discount		269,998
Stockholders' deficiency:
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	1,000,000	1,000,000
Series A Convertible preferred stock, shares designated	200,000	200,000
Series A Convertible preferred stock, shares available to be issued	44,443	44,443
Series A Convertible preferred stock, shares issued	0	0
Series A Convertible preferred stock, shares outstanding	0	0
Series B Convertible preferred stock, shares designated	625,000	625,000
Series B Convertible preferred stock, shares issued	451,879	422,315
Series B Convertible preferred stock, shares outstanding	451,879	422,315
Series B Convertible preferred stock, aggregate liquidation preference	$4,569,175	$4,270,257
Common stock, par value	$0.00	$0.00
Common stock, authorized	100,000,000	100,000,000
Common stock, shares issued	38,749,595	27,708,303
Common stock, shares outstanding	37,570,383	26,529,091
Treasury stock, shares	1,179,212	1,179,212

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Consolidated Statements Of Operations
Net sales	$6,129,660	$10,233,112
Cost of sales	2,492,382	5,111,737
Gross profit	3,637,278	5,121,375
Operating expenses:
Selling, general and administrative expenses	5,370,727	7,554,954
Loss from operations	-1,733,449	-2,433,579
Other income (expense):
Gain on settlement of payables	281,911
Loss on extinguishment of debt		-2,792,900
Interest expense	-331,741	-263,413
Total other expense	-49,830	-3,056,313
Net loss	-1,783,279	-5,489,892
Series B convertible contractual dividends	-298,918	-279,380
Series B convertible deemed dividends		-1,532,722
Loss attributable to common stockholders	($2,082,197)	($7,301,994)
Per share data:
Net loss - basic and diluted	($0.06)	($0.23)
Series B convertible contractual dividends	($0.01)	($0.01)
Series B convertible deemed dividends		($0.07)
Net loss attributable to common stockholders - basic and diluted	($0.07)	($0.31)
Weighted average number of common shares outstanding - basic and diluted	30,036,885	23,401,575

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)	Convertible Series B Preferred Stock	Common Stock	Additional Paid-In Capital	Employee Advances	Treasury Stock	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2012	$395	$13,031	$16,460,385	($18,858)	($3,419,715)	($20,828,674)	($7,793,436)
Beginning Balance, Shares at Dec. 31, 2012	394,685	13,030,397			1,179,212
Stock-based compensation			558,286				558,286
Warrants issued to 2012 private placement investors			487,200				487,200
Issuance of Series B preferred stock as payment-in-kind for dividend, Amount	27		261,057				261,084
Issuance of Series B preferred stock as payment-in-kind for dividend, Shares	27,630
Cashless exercise of warrants into common stock, Amount		10,342	-10,342
Cashless exercise of warrants into common stock, Shares		10,342,931
Contractual dividends on Series B convertible preferred stock						-279,380	-279,380
Beneficial conversion feature and deemed dividend on Series B convertible preferred stock			1,532,722			-1,532,722
Warrants issued as debt discount in connection with notes payable			403,300				403,300
Conversion of notes and accounts payable into common stock and warrants, Amount		833	3,625,067				3,625,900
Conversion of notes and accounts payable into common stock and warrants, Shares		833,000
Issuance of common stock and warrants for cash, Amount		3,502	3,498,473				3,501,975
Issuance of common stock and warrants for cash, Shares		3,501,975
Imputed value of services contributed			350,000				350,000
Change in fair value of collateral securing employee advances				9,857			9,857
Net loss						-5,489,892	-5,489,892
Ending Balance, Amount at Dec. 31, 2013	422	27,708	27,166,147	-9,001	-3,419,715	-28,130,668	-4,365,107
Ending Balance, Shares at Dec. 31, 2013	422,315	27,708,303			1,179,212
Stock-based compensation			830,518				830,518
Shares issued as pursuant to employment agreement, Amount		21	10,625				10,646
Shares issued as pursuant to employment agreement, Shares		21,289
Warrants issued to 2012 private placement investors
Issuance of Series B preferred stock as payment-in-kind for dividend, Amount	30		279,350				279,380
Issuance of Series B preferred stock as payment-in-kind for dividend, Shares	29,564
Contractual dividends on Series B convertible preferred stock						-298,918	-298,918
Warrants issued as debt discount in connection with notes payable			36,000				36,000
Issuance of common stock and warrants for cash, Amount		11,022	1,526,733				1,537,755
Issuance of common stock and warrants for cash, Shares		11,020,003
Imputed value of services contributed			116,666				116,666
Change in fair value of collateral securing employee advances				6,858			6,858
Net loss						-1,783,279	-1,783,279
Ending Balance, Amount at Dec. 31, 2014	$452	$38,751	$29,966,039	($2,143)	($3,419,715)	($30,212,865)	($3,629,481)
Ending Balance, Shares at Dec. 31, 2014	451,879	38,749,595			1,179,212

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net loss	($1,783,279)	($5,489,892)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts		44,535
Provision for employee advance reserve	6,858	9,857
Depreciation and amortization	172,167	158,029
Stock-based compensation	841,164	558,286
Warrants issued to 2012 private placement investors		487,200
Gain on settlement of accounts payable	-281,911
Loss on extinguishment of debt		2,792,900
Imputed value of services contributed	116,666	350,000
Amortization of debt discount	247,631	177,665
Changes in operating assets and liabilities:
Accounts receivable	206,325	-261,894
Inventories	133,064	118,284
Prepaid expenses and other current assets	-1,059	-6,851
Accounts payable - trade	-485,151	336,226
Accounts payable - related parties	623	57,758
Accrued expenses and other current liabilities	39,916	-452,676
Deferred revenue	-88,783	95,792
Net cash used in operating activities	-875,769	-1,024,781
Cash flows from investing activities
Change in restricted cash	-195,088	850,002
Capital expenditures	-2,964
Website development costs	-114,616	-98,423
Net cash provided by (used in) investing activities	-312,668	751,579
Cash flows from financing activities
Principal payments on equipment leases payable	-56,043	-49,122
Proceeds from issuance of notes payable	150,000	700,000
Repayment of notes payable		-2,000,000
Repayment of notes payable - related party	-5,000	-4,000
Repayment of convertible notes payable		-1,000,000
Net proceeds from the sale of common stock	1,537,755	2,651,973
Proceeds from notes payable and other advances - related parties		56,000
Repayment of notes payable and other advances - related parties		-13,905
Net cash provided by financing activities	1,626,712	340,946
Net increase in cash	438,275	67,744
Cash - beginning of period	67,744
Cash - end of period	506,019	67,744
Cash paid for:
Interest	86,692	433,792
Taxes		924
Non-cash investing and financing activities:
Issuance of Series B preferred stock for settlement of accrued dividends	279,380	261,084
Cashless exercise of warrants into common stock		10,342
Warrants issued as debt discount in connection with notes payable	36,000	403,300
Accrual of contractual dividends on Series B convertible preferred stock	298,918	279,380
Deemed dividends on Series B convertible preferred stock		1,532,722
Common stock and warrants issued in exchange of notes and accounts payable		3,625,900
Conversion of Accounts Payable to Notes Payable		$40,000

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
1. Organization and Basis of Presentation	HealthWarehouse.com, Inc., a Delaware company incorporated in 1998, (the “Company”) is a U.S. licensed virtual retail pharmacy (“VRP”) and healthcare e-commerce company that sells brand name and generic prescription drugs as well as over-the-counter (“OTC”) medical products. The Company’s objective is to be viewed by individual healthcare product consumers as a low-cost, reliable and hassle-free provider of prescription drugs and OTC medical products. The Company is presently licensed as a mail-order pharmacy for sales to 50 states in the United States and the District of Columbia.

Going_Concern_and_Managements_

Going Concern and Management's Liquidity Plans	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
2. Going Concern and Management's Liquidity Plans	Since inception, the Company has financed its operations primarily through debt and equity financings and advances from related parties. As of December 31, 2014, the Company had a working capital deficiency of $4,237,165 and an accumulated deficit of $30,212,865. During the years ended December 31, 2014 and 2013, the Company incurred net losses of $1,783,279 and $5,489,892, respectively and used cash in operating activities of $875,769 and $1,024,781, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	Subsequent to December 31, 2014, the Company continues to incur net losses and use cash in operating activities.  Funds from the Company’s private placement offering completed during 2014 have improved the Company’s current cash position and working capital constraints;  however, the funds are not sufficient to satisfy its current obligations.
	On February 13, 2013, the Company received a Notice of Redemption related to its Series C Redeemable Preferred Stock aggregating $1,000,000 (see Note 9). As a result of receiving the Notice of Redemption, the Company must now apply all of its assets to redemption of the Series C Preferred Stock and to no other corporate purpose, except to the extent prohibited by Delaware law governing distributions to stockholders (the Company is not permitted to utilize toward the redemption those assets required to pay its debts as they come due and those assets required to continue as a going concern).
	The Company recognizes it will need to raise additional capital in order to fund operations, meet its payment obligations and execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, attempt to extend note repayments, attempt to negotiate the preferred stock redemption and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.  If the Company is unable to obtain financing on a timely basis, the Company could be forced to sell its assets, discontinue its operation and /or seek reorganization under the U.S. bankruptcy code.
	Accordingly, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily represent realizable or settlement values. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
3. Summary of Significant Accounting Policies	Principles of Consolidation
	The consolidated financial statements include the accounts of HealthWarehouse.com, Inc., Hwareh.com, Inc., Hocks.com, Inc., ION Holding NV, ION Belgium NV and Pagosa Health LLC, its wholly-owned subsidiaries. ION Holding NV and ION Belgium NV are inactive subsidiaries. All material inter-company balances and transactions have been eliminated in consolidation.
	On June 4, 2013, the Company formed a wholly-owned subsidiary called Pagosa Health LLC (“Pagosa”).  On January 14, 2014, the Company closed the Pagosa location and decided to focus on its core consumer prescription business.  The entity was dissolved in 2014.  See Note 10.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the  consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.  The Company’s significant estimates include reserves related to accounts receivable and inventory, the recoverability and useful lives of long-lived assets, the valuation allowance related to deferred tax assets, the valuation of equity instruments and debt discounts.
	Cash
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2014 and 2013, the Company does not have any cash equivalents.
	Restricted Cash
	Restricted cash represents cash held by the Company’s credit card processor as a reserve to cover potential future refunds.
	Allowance for Doubtful Accounts Receivable
	Accounts receivable are shown net of an allowance for doubtful accounts of $47,233 and $250,828 as of December 31, 2014 and 2013, respectively. The Company’s management has established an allowance for doubtful accounts sufficient to cover probable and reasonably estimable losses. The nature of the business is that the majority of the payments are made before the product is sent.  If the financial conditions of customers were to materially deteriorate, an increase in the allowance amount could be required. The allowance for doubtful accounts considers a number of factors, including collection experience, current economic trends, estimates of forecasted write-offs, aging of the accounts receivable, and other factors.
	Inventories
	Inventories consist of finished goods and is stated at the lower of cost (using the first-in, first-out method) or market.  As part of the valuation process, inventory reserves are established to state excess and slow-moving inventory at their estimated net realizable value. The valuation process for excess or slow-moving inventory contains uncertainty because management must use judgment to estimate when the inventory will be sold and the quantities and prices at which the inventory will be sold in the normal course of business.  Inventory reserves are periodically reviewed, reflecting current risks, trends and changes in industry conditions.  When preparing these estimates, management considers historical results, inventory levels and current operating trends.  In the event the estimates differ from actual results, inventory-related reserves may be adjusted and could materially impact the results of operations.
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations in the period of disposal.
	Impairment of Long-Lived Assets
	The Company reviews the carrying value of intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value.  As of December 31, 2014, the Company has not recognized any such impairment.
	Website Development Costs
	The Company capitalizes costs associated with the development of its website. During the years ended December 31, 2014 and 2013, the Company capitalized $114,616 and $98,423, respectively, of website development costs. The Company is amortizing the website development costs on a three year straight-line basis and incurred amortization expense of $55,855 and $14,643 during the years ended December 31, 2014 and 2013, respectively. As of December 31, 2014, unamortized website development costs totaled $142,541.  Estimated future amortization expense related to website development costs is $71,013 in 2015, $56,370 in 2016 and $15,158 in 2017.
	Shipping and Handling Costs
	The Company policy is to provide free standard shipping and handling for most orders shipped during the year. Shipping and handling costs incurred are recognized in selling, general and administrative expenses. Such amounts aggregated $511,636 and $775,083 for the years ended December 31, 2014 and 2013 respectively.
	In certain circumstances, shipping and handling costs are charged to the customer and recognized in revenues. The amounts recognized in revenues for the years ended December 31, 2014 and 2013 were $162,221 and $254,067, respectively.
	Fair Value of Financial Instruments
	Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  These fair value measurements apply to all financial instruments that are measured and reported on a fair value basis.
	Based on the observability of the inputs used in the valuation techniques, financial instruments are categorized according to the fair value hierarchy, which ranks the quality and reliability of the information used to determine fair values.  Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
	Level 1 - Observable inputs such as quoted prices in active markets.
	Level 2 - Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
	Level 3 - Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy.  In such cases, the assignment of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.  The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
	The carrying value of items included in working capital approximates fair value because of the relatively short maturity of these instruments. The convertible debt and notes payable approximate fair value because the terms are substantially similar to comparable debt in the marketplace.
	Income Taxes
	Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.
	U.S. GAAP prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
	Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2014 and 2013. The Company does not expect any significant changes in the unrecognized tax benefits within twelve months of the reporting date.
	The Company classifies interest expense and any related penalties related to income tax uncertainties as a component of income tax expense.  No interest or penalties have been recognized during the years ended December 31, 2014 and 2013.
	Debt Discounts
	The Company records, as a discount to notes and convertible notes, the relative fair value of warrants issued in connection with the issuances and the intrinsic value of any conversion options based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.
	Revenue Recognition
	Revenues for the sales of products are recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is reasonably assured. The Company defers revenue when cash has been received from the customer but delivery has not yet occurred.  Such amounts are reflected as deferred revenues in the accompanying  consolidated financial statements.
	Advertising
	The Company expenses all advertising costs as incurred.  Advertising expense for the years ended December 31, 2014 and 2013 was $103,536 and $1,867, respectively.
	Sales Taxes
	The Company accounts for sales taxes imposed on its goods and services on a net basis in the statement of operations.
	Net Earnings (Loss) Per Share of Common Stock
	Basic net earnings (loss) per share is computed by dividing net earnings (loss) attributable to Common Stockholders by the weighted average number of common shares outstanding during the period.  Diluted net earnings (loss)  per share reflects the potential dilution that could occur if securities or other instruments to issue Common Stock were exercised or converted into Common Stock.  Potentially dilutive securities are excluded from the computation of diluted net earnings (loss) per share if their inclusion would be anti-dilutive and consist of the following:
		December 31,
		2014		2013
	Options		3,944,557		2,543,150
	Warrants		9,339,044		2,342,846
	Series B Convertible Preferred Stock		5,146,902		3,472,953
	Total potentially dilutive shares		18,430,503		8,358,949
	Stock-Based Compensation
	Stock-based compensation expense for all stock-based payment awards is based on the estimated fair value of the award. For employees and directors, the award is measured on the grant date.  For non-employees, the award is measured on the grant date and is then remeasured at each vesting date and financial reporting date.  The Company recognizes the estimated fair value of the award as compensation cost over the requisite service period of the award, which is generally the option vesting term.  The Company generally issues new shares of Common Stock to satisfy option and warrant exercises.
	Preferred Stock
	Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value.  The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity.  At all other times, the Company classifies its preferred shares in stockholders’ deficiency.
	Convertible Instruments
	U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional as that term is described under applicable U.S. GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note.  Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company also records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
	Common Stock Warrants and Other Derivative Financial Instruments
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its Common Stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
	The Company evaluated its free standing warrants to purchase Common Stock to assess their proper classification in the balance sheet as of December 31, 2014 and 2013 using the applicable classification criteria enumerated under U.S. GAAP and determined that the Common Stock purchase warrants contain fixed settlement provisions.
	Recently Issued Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entitiy’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period. If substantial doubt exists, additional disclosure is required. This new standard will be effective for the Company for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. Adoption of this pronouncement is not expected to have a material impact on its consolidated financial statements.
	The FASB has issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The Company has not yet determined the effect of the adoption of this standard and its impact on the Company's consolidated financial position and results of operations.
The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supercedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The Company has not yet determined the effect of the adoption of this standard and its impact on the Company's consolidated financial position and results of operations.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
4. Property and Equipment	Property and equipment consist of the following:
		December 31,						Estimated
		2014			2013			Useful Life
	Computer Software	$	230,299		$	230,299		5 years
	Equipment		544,108			544,108		15 years
	Office Furniture and Equipment		95,754			95,754		7 years
	Computer Hardware		30,710			27,746		5 years
	Leasehold Improvements		303,318			303,318		(a)
	Total		1,204,189			1,201,225
	Less:  accumulated depreciation		(692,903	)		(576,591	)
	Property and Equipment, Net	$	511,286		$	624,634
	(a)    Lesser of useful life or initial term of lease
	Depreciation expense for the above assets for the years ended December 31, 2014 and 2013 was $116,312 and $143,387, respectively.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
5. Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following:
			December 31,
			2014		2013
	Deferred Rent		$	36,053	$	46,254
	Advertising			109,930		75,000
	Salaries and Benefits			82,222		132,048
	Customer Payables			635		39,618
	Dividend Payable			298,918		279,380
	Accrued Interest			48,868		45,616
	Accrued Rent			46,604		-
	Other			57,276		3,136
		Total	$	680,506	$	621,052

Convertible_Notes_Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
6. Convertible Notes Payable	On February 1, 2013, the Company repaid the outstanding principal balance of $1,000,000 of convertible notes plus outstanding accrued interest of $163,861. The convertible notes bore interest at a rate of 7% per annum compounded annually and were due on December 31, 2012.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
7. Notes Payable	On January 15, 2013, the Company failed to make required payments aggregating $2,000,000 in principal and approximately $193,000 of accrued interest due on certain note agreements dated September 2, 2011.  Accordingly, the Company was in default of its obligations under the loan documents.   On February 1, 2013, the Company repaid the notes with an outstanding principal balance of $2,000,000 plus outstanding accrued interest of $199,260. The Company recorded amortization of debt discount associated with the notes payable of $44,363 for the year ended December 31, 2013, using the effective interest method.
	The Company is a party to a Loan and Security Agreement (the “Loan Agreement”) with a lender (the "Lender"). Under the terms of the Loan Agreement, the Company borrowed an aggregate of $750,000 from the Lender (the “Loan”), including $150,000 and $600,000 during the years ended December 31, 2014 and 2013, respectively.  The Loan is evidenced by a promissory note (the “Senior Note”) in the face amount of $750,000 (as amended).  The Senior Note bears interest on the unpaid principal balance of the Note until the full amount of principal has been paid at a floating rate equal to the Prime Rate plus four and one-quarter percent (4.25%) per annum (7.50% as of December 31, 2014).  Under the terms of the Loan Agreement, the Company has agreed to make monthly payments of accrued interest on the first day of every month. The principal amount and all unpaid accrued interest on the Senior Note is payable on March 1, 2015, or earlier in the event of default or a sale or liquidation of the Company.  See Note 14.  The Loan may be prepaid in whole or in part at any time by the Company without penalty.   The Senior Note contains financial covenants which require the Company to meet certain minimum targets for earnings before interest, taxes and non-cash expenses, including depreciation, amortization and stock-based compensation (“EBITDAS”).
	In connection with the Loan Agreement, the Company granted the Lender five-year warrants to purchase an aggregate of 1,125,000 shares of Common Stock at an exercise price of $0.35 per share, of which 225,000 and 900,000 warrants were issued during the years ended December 31, 2014 and 2013, respectively.  The warrants contain customary anti-dilution provisions. The warrants had an aggregate relative fair value of $402,500, of which $36,000 and $366,500 were recorded as debt discounts during the years ended December 31, 2014 and 2013, respectively, and will be amortized using the effective interest method over the term of the Senior Note.  The Company amortized $229,231 and $130,235 of the debt discount as interest expense during the years ended December 31, 2014 and 2013, respectively.  As of December 31, 2014 and 2013, the remaining unamoritized debt discount was $43,034 and $236,265, respectively.  Including the value of warrants issued in connection with Senior Note and subsequent amendments, the Senior Note had an effective interest rate of 40% per annum.
	The Company granted the Lender a first, priority security interest in all of the Company’s assets, in order to secure the Company’s obligation to repay the Loan, including a Deposit Account Control Agreement, which grants the Lender a security interest in certain bank accounts.  The Loan Agreement contains customary negative covenants restricting the Company’s ability to take certain actions without the Lender’s consent, including incurring additional indebtedness, transferring or encumbering assets, paying dividends or making certain other payments, and acquiring other businesses. Upon the occurrence of an event of default, the Lender has the right to impose interest at a rate equal to five percent (5.0%) per annum above the otherwise applicable interest rate (the “Default Rate”). The repayment of the Loan may be accelerated prior to the maturity date upon certain specified events of default, including failure to pay, bankruptcy, breach of covenant, and breach of representations and warranties.
	On March 13, 2013, the Company converted an advance from a related party of $40,000 to a notes payable with a maturity date of December 31, 2013.  The principal balance of the note is due at maturity, with no interest.  The Company made principal payments of $5,000 and $4,000 during the years ended December 31, 2014 and 2013, respectively.  The Company is in discussions with the related party to implement a repayment plan.  Imputed interest expense on this note was de minimis.
	On August 15, 2013, a related party advanced $56,000 to the Company. Subsequently, $7,000 of that advance was repaid to the related party and the Company issued a promissory note for the principal balance of $49,000 (the “Original Note”). The Original Note bears interest at a rate of 10% per annum. The Original Note had a maturity date of November 7, 2013. Through November 21, 2013, the Company repaid $6,905 of the principal of the Original Note and a replacement note was issued for the remaining principal balance of $42,095 (the “Replacement Note”). The Replacement Note waives any existing default under the Original Note and had a maturity date of May 31, 2014. All other terms of the Replacement Note and Original Note are the same.  Interest expense on this note was $3,252 and $1,366 during the years ended December 31, 2014 and 2013, respectively.  The Company is in discussions with the related party to negotiate a repayment plan.
	On October 30, 2013, the Company issued a note payable with a principal amount of $100,000 to a lender. The note bears interest on the unpaid principal balance until the full amount of principal has been paid at a floating rate equal to the Prime Rate plus four and one-quarter percent (4.25%) per annum (as of  December 31, 2014, the Prime Rate was 3.25% per annum). Under the terms of the note, the Company has agreed to make monthly payments of accrued interest on the first day of every month, beginning on December 1, 2013. The principal amount and all unpaid accrued interest is payable on November 1, 2015 but the Company’s obligations are unsecured and are subordinate to its obligations pursuant to the Senior Note described above. The Loan may be prepaid in whole or in part at any time by the Company without penalty. In consideration of the note payable, the Company issued to the lender a five-year warrant to purchase 150,000 shares of Common Stock at an exercise price of $0.35 per share. The warrant contains customary anti-dilution provisions. The warrant had a relative fair value of $36,800 that the Company has recorded as a debt discount which will be amortized using the effective interest method over the term of the October Note. The Company amortized $18,400 and $3,067 of the debt discount as interest expense during the years ended December 31, 2014 and 2013, respectively.  As of December 31, 2014 and 2013, the remaining unamortized debt discount was $15,333 and $33,733, respectively.  Including the value of the warrant, the note had an effective interest rate of 26% per annum

Equipment_Lease_Payable

Equipment Lease Payable	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
8. Equipment Lease Payable	Future minimum lease payments, by year and in the aggregate, under equipment leases, which includes capital leases, as of December 31, 2014, are as follows:
	For year ending December 31,	Lease Payments
	2015	$	76,086
	2016		48,696
	Total	$	124,782
	Less:  Amount representing interest		(14,538	)
	Present value of future lease payments	$	110,244
	Less:  Current portion		(64,101	)
	Long term portion	$	46,143
	As of December 31, 2014, the equipment has a gross and net book value of $305,641 and $240,720, respectively. Depreciation of assets held under capital leases in the amount of $20,377 is included in depreciation expense for both years ended December 31, 2014 and 2013.

Stockholders_Deficiency

Stockholders' Deficiency	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
9. Stockholders' Deficiency	The Company is authorized to issue up to 100,000,000 shares of Common Stock with a par value of $0.001 per share and 1,000,000 shares of preferred stock with a par value of $0.001 per share.  Following the approval of the Board of Directors and stockholders of record as of August 25, 2014, the Company filed a Certificate of Amendment with the Secretary of State of Delaware on October 17, 2014, which increased the number of authorized shares of common stock of the Company from 50,000,000 to 100,000,000.
	Common Stock
	During the year ended December 31, 2013, pursuant to a private placement offering of units that commenced on October 4, 2012 (the “Private Placement”), the Company received an aggregate of $3,501,975 of proceeds related to the sale of 3,501,975 units at a price of $1.00 per unit. The aggregate amount includes $500,000, which was received from an officer, and $850,002, which was received during the fourth quarter of 2012 and classified as restricted cash as of December 31, 2012. Each unit consists of (i) one share of the Company’s Common Stock and (ii) a five-year warrant to purchase three shares of the Company’s Common Stock at an exercise price of $0.25 per share, such that warrants to purchase an aggregate of 10,505,925 shares of Common Stock were issued. Substantially all of the proceeds from the sale of the units were used by the Company to satisfy all of its obligations under certain convertible notes and notes (see Notes 6 and 7). In connection with the Private Placement, an officer has entered into repurchase agreements with certain purchasers of units, pursuant to which he has agreed to repurchase, subject to certain conditions, one-half of these holder’s units at a purchase price of $1.00 per unit if the closing price of the Common Stock is less than $0.25 on five consecutive trading days at any time within one year of February 1, 2013. Cape Bear, which holds a substantial equity position in the Company, also entered into repurchase agreements with certain purchasers, other than the officer, that are substantially similar to the officer’s agreements, except that Cape Bear’s obligations are secured by a lien over certain real estate.
	On March 13, 2013, the Company exchanged $761,000 of notes payable and other advances – related parties and $72,000 of accounts payable to two related parties into an aggregate of 833,000 units at a price of $1.00 per unit. Each unit consists of (i) one share of the Company’s Common Stock, and (ii) a five-year warrant to purchase two and three-quarters shares of the Company’s Common Stock at an exercise price of $0.25 per share (such that warrants to purchase an aggregate of 2,290,750 shares of Common Stock were issued). The $3,625,900 aggregate fair value of the securities issued ($2,639,700 related to the warrants and $986,200 related to the Common Stock) was credited to equity at conversion. The Company recorded a $2,792,900 extinguishment loss which represents the incremental fair value of the securities issued as compared to the carrying value of the liabilities.
	On January 15, 2014, the Company issued 21,289 shares of Common Stock to an employee in accordance with an employment agreement.  The fair value of the shares was $10,646 based on the closing price on the date of issuance which was recorded as stock based compensation expense during the year ended December 31, 2014.
	During the year ended December 31, 2014, pursuant to a private placement offering of units that commenced on July 25, 2014 (the “2014 Private Placement”), the Company received an aggregate of $1,653,000 of gross proceeds (net of expenses of $115,245) related to the sale of 11,020,003 units at a price of $0.15 per unit.  Each unit consists of (i) one share of the Company’s common stock and (ii) a five-year warrant to purchase one-half share of the Company’s common stock at an exercise price of $0.30 per share, such that warrants to purchase an aggregate of 5,509,998 shares of common stock were issued.  The aggregate fair value of the warrants as of the issuance date was $1,096,202.  The Company evaluated these warrants to assess their proper classification using the applicable criteria enumerated by U.S. GAAP and determined that such warrants met the criteria for equity classification.  Proceeds from the sale of the units are to be used to fund the Company’s initiatives in the areas of marketing, website improvement and development, inventory and for general working capital purposes.
	During the year ended December 31, 2014, the Company granted certain options and warrants which, upon settlement, may have exceeded the limit on the authorized number of shares of common stock.  The Company follows a sequencing policy for which in the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of earliest issuance date of potentially dilutive instruments with the earliest grants receiving first allocation of shares.  The Company evaluated such instruments and determined that the fair value of such instruments at the date of issuance and the change in fair value was determined to have a de minimus impact on the Company’s consolidated financial statements.  Subsequent to such issuance and prior to December 31, 2014, the Company obtained stockholder approval to increase the number of authorized shares of common stock of the Company from 50,000,000 to 100,000,000.
	Preferred Stock
	Series A Preferred Stock
	The Company has designated 200,000 of the 1,000,000 authorized shares of preferred stock as Series A Convertible Preferred Stock (“Series A Preferred Stock”). The Series A Preferred Stock is non-voting, has a liquidation preference equal to its purchase price, and does not pay dividends. The holders can call for the conversion of the Series A Preferred Stock at any time and are entitled to half a share of the Company’s Common Stock for each share of Series A Preferred Stock converted. As of December 31, 2013, 44,443 shares of Series A Preferred Stock are available to be issued. There is no Series A Preferred Stock outstanding as of December 31, 2014 or 2013.
	Series B Preferred Stock
	The Company has designated 625,000 of the 1,000,000 authorized shares of preferred stock as Series B Convertible Preferred Stock (“Series B Preferred Stock”). The Series B Preferred Stock has voting rights equal to one vote for each common share equivalent, has a liquidation preference equal to its purchase price, and receives preferred dividends equal to 7% of all outstanding shares in either cash or payment-in-kind. The holders can call for the conversion of the Series B Preferred Stock at any time and are entitled to five shares of the Company’s Common Stock for each share of Series B Preferred Stock converted. In addition, the Series B Preferred Stock is subject to weighted average anti-dilution protection whereby if shares of Common Stock are sold below the current conversion price, the conversion price is reduced pursuant to a pre-defined formula. As of December 31, 2014 and 2013, Series B holders were entitled to convert into 11.39 and 8.22 shares, respectively, of the Company’s Common Stock for each share of Series B Preferred Stock due to the anti-dilution provision. The anti-dilution provision represents a contingent beneficial conversion feature.  As of December 31, 2014, an incremental 2,887,507 shares of Common Stock are issuable at conversion of the Series B Convertible Preferred Stock as compared to the original terms.   Using the commitment date Common Stock price in effect, the commitment date value of the incremental shares is $7,288,068. However, recognition of beneficial conversion features is limited to the aggregate gross proceeds allocated to the preferred stock of $3,199,689 (422,315 shares of Series B Convertible Preferred Stock times $9.45 per share less the proceeds allocated to the warrants of $791,188) less the $1,666,967 beneficial conversion feature already recognized on the original 365,265 shares of Series B Preferred Stock (prior to the issuance of additional shares as payment-in-kind in lieu of cash dividends).  Due to these limitations, a beneficial conversion feature of only $1,532,722 was recorded for the year ended December 31, 2013.
	As of December 31, 2014 and 2013, the Company had accrued contractual dividends of $298,918 and $279,380, respectively, related to the Series B Preferred Stock.  On January 1, 2015, and 2014, the Company issued 31,633 and 29,564 shares of Series B convertible preferred stock valued at approximately $299,000 and $279,000, respectively, representing approximately $0.66 in value per share of Series B Preferred Stock outstanding on each date, to the Series B convertible preferred stock owners as payment in kind for dividends.
	Series C Preferred Stock
	On October 17, 2011, the Company filed a Certificate of Designation of Preferences, Rights and Limitations with the Secretary of State of the State of Delaware fixing the rights, preferences and restrictions of a newly formed class of Series C Preferred Stock. The Certificate of Designation designates 10,000 shares of the Company's preferred stock as Series C Preferred Stock to be issued at an original issue price of $100 per share. The Series C Preferred Stock has voting rights equal to one vote for each share held, has a liquidation preference equal to its purchase price, and has certain redemption rights available at the option of the holder. The holder could make a mandatory redemption request at any time on or after  January 15, 2013. The Series C Preferred Stock is non- convertible and does not pay dividends.
	On October 17, 2011, the Company received net cash proceeds of $1,000,000 for the sale of 10,000 shares of Series C Preferred Stock to a greater than 10% stockholder of the Company. Since certain of the Company’s preferred shares contain redemption rights which are not solely within the Company’s control, these issuances of preferred stock were initially presented as temporary equity. In connection with the issuance, the investor received five-year immediately exercisable warrants to purchase 270,000 shares of the Company’s Common Stock at an exercise price of $2.90 per share and which had a relative fair value of $526,522 on the date of grant. The $526,522 relative fair value was recorded as a discount against the Series C Preferred Stock and was initially amortized as deemed dividends over the period through January 15, 2013.
	On February 13, 2013, the Company received a Notice of Redemption of Series C Preferred Stock. As a result of the Convertible Notes coming due and not being paid on December 31, 2012, the Company accelerated the accretion rate of the deemed dividend on the Redeemable Preferred Stock – Series C and reclassified the Redeemable Preferred Stock – Series C from temporary equity to current liabilities.
	Incentive Compensation / Stock Option Plans
	The 2009 Incentive Compensation Plan (the “2009 Plan”) was approved on May 15, 2009 and June 4, 2009, and the increase in the total number of shares of Common Stock issuable pursuant to the 2009 Plan to 2,881,425 was approved on October 4, 2010 and September 20, 2011 by the Board of Directors and Stockholders, respectively.
	The 2009 Plan imposes individual limitations on the amount of certain awards. Under these limitations during any fiscal year of the Company, the number of options, stock appreciation rights, shares of restricted stock, shares of deferred stock, performance shares and other stock based-awards granted to any one participant under the 2009 Plan may not exceed 250,000 shares, subject to adjustment in certain circumstances. The maximum amount that may be paid out as performance units in any 12-month performance period is an aggregate value of $2,000,000, and the maximum amount that may be paid out as performance units in any performance period greater than 12 months is an aggregate value of $4,000,000. The maximum term of each option or stock appreciation right, the times at which each option or stock appreciation right will be exercisable, and provisions requiring forfeiture of unexercised options or stock appreciation rights at or following termination of employment generally are fixed by the board of directors or committee of the Company’s board of directors designated to administer the 2009 Plan (the “Committee”), except that no option or stock appreciation right may have a term exceeding ten years. The exercise price per share subject to an option and the grant price of a stock appreciation rights are determined by the Committee, but in the case of an incentive stock option (ISO) must not be less than the fair market value of a share of Common Stock on the date of grant.
	Following the approval of the Board of Directors and stockholders of record as of August 25, 2014, the Company adopted the 2014 Equity Incentive Plan (the “2014 Plan”) which made a total of 6,000,000 shares of common stock authorized and available for issuance pursuant to awards granted under the 2014 Plan.
	The 2014 Plan limit imposes individual limitations on the amount of certain awards. Under these limitations during any fiscal year of the Company, the number of options, stock appreciation rights, shares of restricted stock, shares of deferred stock, performance shares and other stock based-awards granted to any one participant under the 2014 Plan may not exceed 1,500,000 shares, subject to adjustment in certain circumstances. The maximum number of shares that may be awarded that are not subject to performance targets is an aggregate of 1,200,000 shares.   The maximum term of each option or stock appreciation right, the times at which each option or stock appreciation right will be exercisable, and provisions requiring forfeiture of unexercised options or stock appreciation rights at or following termination of employment generally are fixed by the Committee designated to administer the 2014 Plan, except that no option or stock appreciation right may have a term exceeding ten years. The exercise price per share subject to an option and the grant price of a stock appreciation rights are determined by the Committee, but in the case of an incentive stock option (ISO) must not be less than the fair market value of a share of Common Stock on the date of grant.
	Stock Options
	Grants
	On February 15, 2013 and December 23, 2013, the Company granted options to employees to purchase an aggregate of 430,500 shares of Common Stock under the 2009 Plan at an exercise price ranging from $0.53 to $1.60 per share for an aggregate grant date value of $425,824. The options vest over a three year period and have a term of ten years.
	On June 19, 2013 and October 30, 2013, the Company granted options to certain directors to purchase 505,000 shares of Common Stock under the 2009 Plan at an exercise price ranging from $0.30 to $1.45 per share for a grant date value of $198,820.  The options vest over a one to three year period and have a term of ten years.
	On August 27, 2014 and October 23, 2014, the Company granted options to directors of the Company to purchase an aggregate of 1,687,857 shares of common stock under the 2009 Plan and 2014 Plan at an exercise price of between $0.12 to $0.16 per share for an aggregate grant date value of $266,472.  The options have a vesting period ranging from immediate to three months and have a term of ten years.
	On October 23, 2014, the Company granted options to an employee of the Company to purchase an aggregate of 250,000 shares of common stock under the 2009 Plan at an exercise price of $0.18 per share for an aggregate grant date value of $35,825.  The options have a vesting period of one year and have a term of five years.
	Valuation and Amortization
	Option valuation models require the input of highly subjective assumptions.  The fair value of the stock-based payment awards is estimated utilizing the Black-Scholes option model.  The volatility component of this calculation is derived from the historical trading prices of  the Company’s own Common Stock.  The Company accounts for the expected life of options in accordance with the “simplified” method which enables the use of the simplified method for “plain vanilla” share options as defined in Staff Accounting Bulletin No. 107.  The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.
	In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest.  In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding.  If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.  The Company estimated forfeitures related to option grants at a weighted average annual rate of 4% per year for options granted during the years ended December 31, 2014 and 2013.
	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			For Year Ended
			December 31,
			2014		2013
	Risk free interest rate		0.97% to 2.29%		1.13% to 2.03%
	Dividend yield		0.00%		0.00%
	Expected volatility		190% to 191.0%		162.0% to 175.0%
	Expected life in years		3.0 to 10.0		5.5 to 6.0
	The weighted average fair value of the stock options granted during the years ended December 31, 2014 and 2013 was $0.16 and $0.91 per share, respectively.
	Stock-based compensation expense related to stock options was recorded in the  consolidated statements of operations as a component of selling, general and administrative expenses and totaled $698,015 and $558,286 for the years ended December 31, 2014 and 2013, respectively.
	As of December 31, 2014, stock-based compensation expense related to stock options of $1,135,635 remains unamortized, including $244,066 which is being amortized over the weighted average remaining period of 1.1 years.  The remaining $891,569 is related to a performance based option where vesting is currently deemed to be improbable and no amount is being amortized.
	Summary
	A summary of the stock option activity during the years ended December 31, 2014 and 2013 is presented below:
										Weighted
							Weighted			Average
							Average			Remaining	Aggregate
			Number of				Exercise			Life	Intrinsic
			Options				Price			In Years	Value
	Outstanding, January 1, 2013			2,183,899			$	2.76
	Granted			935,500				0.91
	Exercised			-				-
	Forfeited			(576,249	)			3.96
	Outstanding, December 31, 2013			2,543,150			$	2.37
	Outstanding, January 1, 2014			2,543,150			$	2.37
	Granted			1,937,857				0.13
	Exercised			-				-
	Forfeited			(536,450	)			2.37
	Outstanding, December 31, 2014			3,944,557			$	1.27		7.4	$                -
	Exercisable, December 31, 2014			3,135,876			$	1.11		8.0	$                -
	The following table presents information related to stock options at December 31, 2014:
					Options Outstanding							Options Exercisable
					Weighted							Weighted		Weighted
	Range of				Average				Outstanding			Average		Average		Exercisable
Exercise				Exercise				Number of			Exercise		Remaining Life		Number of
Price				Price				Options			Price		In Years		Options
$	0.12 - $2.20			$	0.36				2,870,807		$	0.26		9.2		2,339,126
$	2.21 - $3.80				3.23				757,750			2.95		3		507,750
$	3.81 - $6.99				4.88				316,000			4.73		7		289,000
$	0.12 - $6.99			$	1.27				3,944,557		$	1.11		8		3,135,876
Warrants
Valuation
In applying the Black-Scholes option pricing model to stock warrants granted, the Company used the following weighted average assumptions:
Grants
		For Year Ended
		December 31,
		2014		2013
Risk free interest rate		1.52% to 2.52%		0.74% to 2.84%
Dividend yield		0.00%		0.00%
Expected volatility		171% to 192%		146% to 173.0%
Expected life in years		5.0 to 8.5		5.0 to 9.5
On February 15, 2013, the Company granted vested five-year warrants to purchase an aggregate of 408,345 shares of Common Stock at an exercise price of $1.00 per share to investors who purchased shares in private placements at $4.50 per share during 2012. The warrants had an issuance date fair value of $487,200 which was expensed immediately.
On August 25, 2014 and October 23, 2014, the Company granted vested five-year warrants to purchase an aggregate of 661,200 shares of Common Stock at an exercise price of $0.15 per share to a consultant related to services provided related to the 2014 Private Placement.  The warrants had an issuance date fair value of $132,893 which was treated as a cost of capital.
On August 25, 2014, the Company granted vested five-year warrants to purchase an aggregate of 600,000 shares of Common Stock at an exercise price of $0.25 per share to a consultant related to investor relations services to be provided.  The warrants had an issuance date fair value of $133,225 which was expensed immediately as stock based compensation.
The weighted average fair value of the stock warrants granted during the years ended December 31, 2014 and 2013, respectively, was $0.20 and $1.34 per share.
Exercise
During the year ended December 31, 2013, the Company issued an aggregate of 10,342,931 shares of Common Stock to several holders of warrants who elected to exercise warrants to purchase 12,505,023 shares of Common Stock on a "cashless" basis under the terms of the warrants. The warrants had exercise prices of $0.25 per share (11,346,675 gross shares), $0.35 per share (750,000 gross shares), and $1.00 per share (408,348 gross shares).
The aggregate intrinsic value of the warrants exercised was $16,983,736 for the year ended December 31, 2013.
A stock-based compensation benefit related to the mark-to-market adjustment for consultant warrants for the year ended December 31, 2014 was recorded in the consolidated statements of operations as a component of selling, general and administrative expenses and totaled $722. During the years ended December 31, 2014 and 2013, the Company recorded aggregate stock-based compensation expense of $132,503 and $490,420, respectively, related to warrants.  As of December 31, 2014, stock-based compensation expense related to warrants of $577,523 remains unamortized, including $683 which is being amortized over the weighted average remaining period of 0.8 years.  The remaining $576,840 is related to a performance based warrant where vesting is currently deemed to be improbable and no amount is being amortized.
A summary of the stock warrant activity during the years ended December 31, 2014 and 2013, respectively, is presented below:
									Weighted
						Weighted			Average
						Average			Remaining
		Number of				Exercise			Life	Intrinsic
		Warrants				Price			In Years	Value
Outstanding, January 1, 2013			592,846			$	3.01
Granted			14,255,023			$	0.28
Exercised			(12,505,023	)		$	0.28
Forfeited			-			$	-
Outstanding, January 1, 2014			2,342,846			$	0.94
Granted			6,996,198			$	0.28
Exercised			-				-
Forfeited			-				-
Outstanding, December 31, 2014			9,339,044			$	0.45		4.2	$                -
Exercisable, December 31, 2014			9,079,044			$	0.38		4.3	$                -
The following table presents information related to stock warrants at December 31, 2014:
				Warrants Outstanding							Warrants Exercisable
				Weighted							Weighted		Weighted
Range of				Average				Outstanding			Average		Average		Exercisable
Exercise				Exercise				Number of			Exercise		Remaining Life		Number of
Price				Price				Warrants			Price		In Years		Warrants
$	0.15 - $0.35			$	0.28				8,746,198		$	0.28		4.4		8,746,198
$	0.36 - $3.00				2.91				562,846			2.91		1.7		312,846
$	3.01 - $4.95				4.95				30,000			4.95		2.8		20,000
$	0.15 - $4.05				0.45				9,339,044		$	0.38		4.3		9,079,044
Services Contributed
Effective January 1, 2013, the Company’s Chief Executive Officer of the Company waived payment for services contributed during 2013.  On April 28, 2014, the Compensation Committee approved the payment of an annual salary of $150,000 to the Company’s Chief Executive Officer, effective May 1, 2014.  As a result, the Company imputed the value of the services contributed and recorded salary expense $116,666 and $350,000 for years ended December 31, 2014 and 2013, respectively, with a corresponding credit to stockholders’ deficiency.

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
10. Commitments and Contingent Liabilities	Operating Leases
	The Company is a party to a lease agreement for approximately 62,600 square feet of office and storage space (as amended). The amended monthly lease rate of $9,224 was in effect from January 2012 through December 2013. The monthly lease rate increases to $10,671 for years 2014 and 2015 and to $11,975 in year 2016.  The Company accounts for rent expense using the straight line method of accounting, deferring the difference between actual rent due and the straight line amount. The lease expires on January 1, 2017. Deferred rent payable of $36,053 and $46,254 as of December 31, 2014 and 2013, respectively, has been included in accrued expenses and other current liabilities on the consolidated balance sheets.
	On March 13, 2013, the Company gave notice of early termination for a lease agreement for a corporate apartment dated May 31, 2011. Accordingly, the lease expired on March 31, 2013. The Company did not incur any penalties related to the early termination of the lease agreement.
	On June 7, 2013, Pagosa signed a three year lease for $1,000 per month to house an office, pharmacy as well as inventory and is located in Lawrenceburg, IN.  On July 8, 2013, the parties agreed to extend the lease for two additional years, such that the new termination date is now June 7, 2018.  On January 14, 2014, the Company closed Pagosa and vacated the Lawrenceburg facility. The Company is currently in discussions with the landlord regarding termination of the lease related to the building.   The present value of the remaining lease payments of $46,604 was expensed during the year ended December 31, 2014, and is reflected as a component of accrued expenses and other liabilities on the consolidated balance sheet as of December 31, 2014.
	On December 15, 2014, the Company entered into a sublease agreement for 34,106 square feet of warehouse space at the Company’s corporate headquarters in Florence, Kentucky. The initial term of the sublease expires on June 14, 2015 with rent of $9,948 per month. After the expiration of the initial term, the tenant may extend the term of the sublease agreement on a month to month basis.
	Future minimum payments, by year and in the aggregate, under operating leases as of December 31, 2014 are as follows:
	For year ending December 31,	Amount
	2015	$	140,052
	2016		155,700
	2017		12,000
	2018		5,000
	Total future minimum lease payments	$	312,752
	During the years ended December 31, 2014 and 2013, the Company recorded aggregate rent expense of $250,576 and $174,661, respectively.
	Litigation
	In the ordinary course of business, we may become subject to lawsuits and other claims and proceedings that might arise from litigation matters or regulatory audits. Such matters are subject to uncertainty and outcomes are often not predictable with assurance. Our management does not presently expect that any such matters will have a material adverse effect on the Company’s consolidated financial condition or consolidated results of operations. We are not currently involved in any pending or threatened material litigation or other material legal proceedings nor have we been made aware of any penalties from regulatory audits, except as described below.
	On February 9, 2012, two of our former stockholders, Rock Castle Holdings, LLC and Jason Smith (collectively “Plaintiffs”), filed suit against us in the Hamilton County, Ohio Court of Common Pleas, alleging that we had breached the terms of certain incentive options we granted to the Plaintiffs in connection with our now-terminated oral consulting arrangements with the Plaintiffs, by among other things, refusing Plaintiffs’ purported exercise of options to purchase 233,332 shares of our Common Stock at an exercise price of $2.00 per share in December 2011.  Plaintiffs requested that, among other things, the court require us to permit the exercise of the 233,332 options.  Plaintiffs also provided an expert report indicating damages of $2.086 million.  On December 1, 2014, the Company executed a settlement agreement with the Plaintiff for $150,000 to be paid in unequal monthly installments through June 10, 2015.  The settlement amount was included in Selling, General and Administrative expense for the year ended December 31, 2014 and the unpaid balance of $135,000 was included in accounts payable as of December 31, 2014.
	On October 9, 2012, American Express Travel Related Services Company, Inc. brought legal action against the Company in the Boone County, Kentucky Circuit Court. The action seeks to recover the unpaid balance on a credit card account in the amount of $87,029, plus interest and costs.  The litigation was resolved on July 10, 2013 by a negotiated settlement.  The remaining balance of $2,029 is accrued in the accompanying consolidated balance sheet as of December 31, 2014 and was repaid in full in January 2015.
	On March 20, 2013, a complaint was filed in the Delaware Court of Chancery by two of our shareholders, HWH Lending, LLC and Milfam I L.P., seeking to compel the holding of an annual meeting of stockholders for the election of directors under Delaware law.  We filed an answer to the complaint on April 12, 2013.  On May 13, 2013, we publicly announced that the Board of Directors had set the date for our next annual meeting of stockholders as August 15, 2013 at 11:00 a.m. Eastern time.  In lieu of further litigation, on July 18, 2013, the parties submitted to the court a proposed order, subsequently entered by the Court, confirming August 15, 2013 as the annual meeting date and establishing certain procedures related to the annual meeting.  In accordance with the Court order, our annual meeting of stockholders was held on August 15, 2013 at which time Lalit Dhadphale, Youssef Bennani, Joseph Savarino, and Ambassador Ned Siegel each received a plurality of the total votes cast at the annual meeting and each was elected as a director by our stockholders.  On September 24, 2013, this action was dismissed without prejudice by a joint stipulation of dismissal.
	The Company was a party to a putative stockholder derivative action that was filed in the Court of Chancery of the State of Delaware on May 7, 2013 against certain directors and our chief executive officer and against us, as a nominal defendant.   The complaint alleged claims for breach of fiduciary duty, entrenchment and corporate waste arising out of the alleged failure to conduct annual meetings, SEC filing obligations, advances to a former employee and a $500,000 secured loan to us which the entire board of directors approved.  The derivative complaint sought unspecified compensatory damages and other relief.  On January 8, 2014, in a stipulation and order of dismissal, the action was dismissed with prejudice to plaintiff, with each party bearing its own attorneys' fees and costs.
	On May 15, 2013, a former consultant filed suit in Boone County, Kentucky Circuit Court alleging breach of contract and unjust enrichment for unpaid consulting fees and expenses of approximately $55,000.  On September 29, 2014, the Company executed a settlement agreement with the former consultant for $25,000 which was payable in monthly installments through March 1, 2015.
	On October 11, 2013, two of our former directors sent a letter demanding repayment of legal fees and expenses ($80,766 of previously incurred expenses plus future expenses) pursuant to certain Company indemnification and advancement provisions.  On November 13, 2013, following the receipt of the Special Committee report, we agreed to indemnify the two former directors for their reasonable legal fees and expenses up to $85,000 less any amount paid to the directors under our directors’ and officers’ insurance policy.  On November 14, 2013, the former directors filed a verified complaint and a motion for expedited proceedings for advancement in the Delaware Court of Chancery.   In a stipulation and order dated December 23, 2013, these proceedings were concluded, and the Company agreed to pay the former directors’ reasonable attorneys’ fees and expenses, which included (i) $87,500 in connection with certain claims and demands and (ii) $27,500 incurred in the Delaware action. Such amounts have been repaid in full as of the date of this report.
	Settlement Agreement
	On February 22, 2013, the Company entered into a settlement agreement with a counterparty for amounts owed related to the return of expired goods and inventory and the Company wrote down the accounts receivable to the settlement amount as of December 31, 2012. On February 28, 2013, the Company received $50,000 in connection with the agreement in complete satisfaction of all outstanding and past due accounts receivable from the counterparty, such that there was no balance due to the Company as of December 31, 2013.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
11. Concentrations	The Company maintains deposits in financial institutions which are insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in these financial institutions in excess of the amount insured by the FDIC.
	During the year ended December 31, 2014, two vendors represented 68% and 14% of total inventory purchases. During the year ended December 31, 2013, two vendors represented 61% and 14% of total inventory purchases, respectively.
	One vendor represented 36% and 26% of the accounts payable balance as of December 31, 2014 and 2013, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
12. Related Party Transactions	Effective September 4, 2014, the Company entered into a Consulting Agreement with a stockholder to provide consulting services related to business development and marketing activities for the Company and other duties as agreed to by management.   The Company is required to pay the related party a monthly fee of $10,000 plus expense reimbursement.  Subsequent to the effective date, the related party agreed to defer the payment of the monthly fee for a period of four months beginning with the November 4, 2014 payment.  The deferred fees will be payable on the earlier of the termination date and the second anniversary of the effective date.  The Consulting Agreement has an initial term of one year and can be automatically renewed for a one year period unless terminated by either party.  The Agreement may be terminated by the Company by providing a sixty day notice prior to the first anniversary of the effective date.  During the year ended December 31, 2014, the Company incurred consulting and other expenses of $21,110 and paid the related party such amount.
	Beginning July 1, 2013, a director is to be paid $3,000 per month and is entitled to expense reimbursements as compensation for serving on the Company’s Board committees. The director served on an Independent Committee (See Footnote 10 – Litigation) starting in July 2013 and concluding in November 2013.  As a result, the director earned $12,000 during the year ended December 31, 2013.
	Between June 2009 and April 2012, an employee who is the son of the managing member of a limited liability company that beneficially owns over 5% of the Company’s Common Stock received advances from the Company in various forms which totaled $391,469 including interest.  Principal repayments towards the outstanding advances aggregating $235,000 have been made through September 30, 2014.  In April 2012, this employee voluntarily resigned from the Company. The individual agreed to repay the remaining balance with interest based on prime rate on the first business day of the calendar quarter. The amount has been included in Stockholders’ Deficiency as the Company has determined to exercise its rights through a pledge agreement for 42,860 shares as collateral.  At December 31, 2014 and 2013, the Company estimated the value of the collateral at $2,143 and $9,001, respectively.
	From March 2011 to April 2013, a wife of a director served as the agent for the Company's D&O insurance. During year ended December 31, 2013, the Company recorded insurance premium expense of $24,329.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
13. Income Taxes	The income tax provision (benefit) for the years ended December 31, 2014 and 2013 was as follows:
		For The Year Ended
		December 31,
		2014			2013
	Federal:
	Current	$	-		$	-
	Deferred		(387,752	)		(625,702	)
	State and local:
	Current		-			-
	Deferred		(161,244	)		(36,806	)
			(548,996	)		(662,508	)
	Change in valuation allowance		548,996			662,508
	Income tax provision (benefit)	$	-		$	-
	The effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows:
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	5,315,823		$	4,966,018
	Stock-based compensation		722,782			466,078
	Inventory reserves		6,090			10,949
	Allowance for bad debt		17,948			89,899
	Deferred Rent		14,108			-
	Contingent Liability		1,910			-
	Charitable contribution carryforwards		5,772			5,630
	Accruals		31,007			27,352
	Total deferred tax assets		6,115,440			5,565,926
	Valuation allowance		(6,088,174	)		(5,539,178	)
	Deferred tax assets, net of valuation allowance		27,266			26,748
	Deferred tax liabilities:
	Property and equipment		(27,266	)		(26,748	)
	Net deferred tax assets	$	-		$	-
	Change in valuation allowance	$	548,996		$	666,508
	The Company assesses the likelihood that deferred tax assets will be realized.  To the extent that realization is not likely, a valuation allowance is established.  Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2014 and 2013.
	The Company is in the process of filing its federal and state tax returns for the years ended December 31, 2014, 2013, and 2012.  The Net operating losses (“NOLs”) for these years will not be available to reduce future taxable income until the returns are filed.  Assuming these returns are filed, as of December 31, 2014 and 2013, the Company has approximately $14,736,276 and $13,770,000, respectively, of federal NOLs that may be available to offset future taxable income.  The federal net operating loss carryforwards, if not utilized, will expire from 2027 to 2034.  As of December 31, 2014 and 2013, the Company has approximately $7,637,237 and $3,585,000 of state net operating loss carryforwards available to offset future taxable income.  The state NOLs, if not utilized, will expire beginning in 2031.
	In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s net operating loss carryforwards could be limited in the event of a change in ownership.  Based upon a study that analyzed the Company’s stock ownership, a change of ownership was deemed to have occurred in 2011.  This change of ownership created an annual limitation of approximately $2,116,000 on the usage of the Company’s losses which are available through 2031.  A full Section 382 analysis has not been prepared since 2011 and any NOLs arising since 2011 could be subject to limitation under Section 382.
	For the years ended December 31, 2014 and 2013, the expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax expense (benefit) as follows:
		For The Year Ended
		December 31,
		2014			2013
	US federal statutory rate		(34.0	%)		(34.0	%)
	State tax rate, net of federal benefit		(4.0	%)		(2.0	%)
	Permanent differences
	- Stock based compensation		4.8	%		3.2	%
	- Debt extinquishment		0	%		18.3	%
	- Other		2.4	%		2.5	%
	Change in valuation allowance		30.8	%		12	%
	Income tax provision (benefit)		0	%		0	%

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
14. Subsequent Events	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.
	Notes Payable
	Effective March 1, 2015, a lender agreed to extend the maturity date of the Senior Note from March 1, 2015 to September 1, 2015.  As part of the extension, financial covenants were set which require the Company to meet certain minimum targets for EBITDAS for the calendar quarters ending on March 31 and June 30, 2015. In consideration of the Lender extending the maturity date of the Senior Note, the Company granted the lender a five-year warrant to purchase 500,000 shares of Common Stock at an exercise price of $0.10 per share. The warrant contains customary anti-dilution provisions.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies Policies
Principles of Consolidation	The consolidated financial statements include the accounts of HealthWarehouse.com, Inc., Hwareh.com, Inc., Hocks.com, Inc., ION Holding NV, ION Belgium NV and Pagosa Health LLC, its wholly-owned subsidiaries. ION Holding NV and ION Belgium NV are inactive subsidiaries. All material inter-company balances and transactions have been eliminated in consolidation.
	On June 4, 2013, the Company formed a wholly-owned subsidiary called Pagosa Health LLC (“Pagosa”).  On January 14, 2014, the Company closed the Pagosa location and decided to focus on its core consumer prescription business.  The entity was dissolved in 2014.  See Note 10.
Use of Estimates	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the  consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.  The Company’s significant estimates include reserves related to accounts receivable and inventory, the recoverability and useful lives of long-lived assets, the valuation allowance related to deferred tax assets, the valuation of equity instruments and debt discounts.
Cash	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2014 and 2013, the Company does not have any cash equivalents.
Restricted Cash	Restricted cash represents cash held by the Company’s credit card processor as a reserve to cover potential future refunds.
Allowance for Doubtful Accounts Receivable	Accounts receivable are shown net of an allowance for doubtful accounts of $47,233 and $250,828 as of December 31, 2014 and 2013, respectively. The Company’s management has established an allowance for doubtful accounts sufficient to cover probable and reasonably estimable losses. The nature of the business is that the majority of the payments are made before the product is sent.  If the financial conditions of customers were to materially deteriorate, an increase in the allowance amount could be required. The allowance for doubtful accounts considers a number of factors, including collection experience, current economic trends, estimates of forecasted write-offs, aging of the accounts receivable, and other factors.
Inventories	Inventories consist of finished goods and is stated at the lower of cost (using the first-in, first-out method) or market.  As part of the valuation process, inventory reserves are established to state excess and slow-moving inventory at their estimated net realizable value. The valuation process for excess or slow-moving inventory contains uncertainty because management must use judgment to estimate when the inventory will be sold and the quantities and prices at which the inventory will be sold in the normal course of business.  Inventory reserves are periodically reviewed, reflecting current risks, trends and changes in industry conditions.  When preparing these estimates, management considers historical results, inventory levels and current operating trends.  In the event the estimates differ from actual results, inventory-related reserves may be adjusted and could materially impact the results of operations.
Property and Equipment	Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations in the period of disposal.
Impairment of Long-Lived Assets	The Company reviews the carrying value of intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value.  As of December 31, 2014, the Company has not recognized any such impairment.
Website Development Costs	The Company capitalizes costs associated with the development of its website. During the years ended December 31, 2014 and 2013, the Company capitalized $114,616 and $98,423, respectively, of website development costs. The Company is amortizing the website development costs on a three year straight-line basis and incurred amortization expense of $55,855 and $14,643 during the years ended December 31, 2014 and 2013, respectively. As of December 31, 2014, unamortized website development costs totaled $142,541.  Estimated future amortization expense related to website development costs is $71,013 in 2015, $56,370 in 2016 and $15,158 in 2017.
Shipping and Handling Costs	The Company policy is to provide free standard shipping and handling for most orders shipped during the year. Shipping and handling costs incurred are recognized in selling, general and administrative expenses. Such amounts aggregated $511,636 and $775,083 for the years ended December 31, 2014 and 2013 respectively.
	In certain circumstances, shipping and handling costs are charged to the customer and recognized in revenues. The amounts recognized in revenues for the years ended December 31, 2014 and 2013 were $162,221 and $254,067, respectively.
Fair Value of Financial Instruments	Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  These fair value measurements apply to all financial instruments that are measured and reported on a fair value basis.
	Based on the observability of the inputs used in the valuation techniques, financial instruments are categorized according to the fair value hierarchy, which ranks the quality and reliability of the information used to determine fair values.  Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
	Level 1 - Observable inputs such as quoted prices in active markets.
	Level 2 - Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
	Level 3 - Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy.  In such cases, the assignment of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.  The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
	The carrying value of items included in working capital approximates fair value because of the relatively short maturity of these instruments. The convertible debt and notes payable approximate fair value because the terms are substantially similar to comparable debt in the marketplace.
Income Taxes	Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.
	U.S. GAAP prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
	Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2014 and 2013. The Company does not expect any significant changes in the unrecognized tax benefits within twelve months of the reporting date.
	The Company classifies interest expense and any related penalties related to income tax uncertainties as a component of income tax expense.  No interest or penalties have been recognized during the years ended December 31, 2014 and 2013.
Debt Discounts	The Company records, as a discount to notes and convertible notes, the relative fair value of warrants issued in connection with the issuances and the intrinsic value of any conversion options based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.
Revenue Recognition	Revenues for the sales of products are recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is reasonably assured. The Company defers revenue when cash has been received from the customer but delivery has not yet occurred.  Such amounts are reflected as deferred revenues in the accompanying  consolidated financial statements.
Advertising	The Company expenses all advertising costs as incurred.  Advertising expense for the years ended December 31, 2014 and 2013 was $103,536 and $1,867, respectively.
Sales Taxes	The Company accounts for sales taxes imposed on its goods and services on a net basis in the statement of operations.
Net Earnings (Loss) Per Share of Common Stock	Basic net earnings (loss) per share is computed by dividing net earnings (loss) attributable to Common Stockholders by the weighted average number of common shares outstanding during the period.  Diluted net earnings (loss)  per share reflects the potential dilution that could occur if securities or other instruments to issue Common Stock were exercised or converted into Common Stock.  Potentially dilutive securities are excluded from the computation of diluted net earnings (loss) per share if their inclusion would be anti-dilutive and consist of the following:
		December 31,
		2014		2013
	Options		3,944,557		2,543,150
	Warrants		9,339,044		2,342,846
	Series B Convertible Preferred Stock		5,146,902		3,472,953
	Total potentially dilutive shares		18,430,503		8,358,949
Stock-Based Compensation	Stock-based compensation expense for all stock-based payment awards is based on the estimated fair value of the award. For employees and directors, the award is measured on the grant date.  For non-employees, the award is measured on the grant date and is then remeasured at each vesting date and financial reporting date.  The Company recognizes the estimated fair value of the award as compensation cost over the requisite service period of the award, which is generally the option vesting term.  The Company generally issues new shares of Common Stock to satisfy option and warrant exercises.
Preferred Stock	Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value.  The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity.  At all other times, the Company classifies its preferred shares in stockholders’ deficiency.
Convertible Instruments	U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional as that term is described under applicable U.S. GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note.  Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company also records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
Common Stock Warrants and Other Derivative Financial Instruments	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its Common Stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
	The Company evaluated its free standing warrants to purchase Common Stock to assess their proper classification in the balance sheet as of December 31, 2014 and 2013 using the applicable classification criteria enumerated under U.S. GAAP and determined that the Common Stock purchase warrants contain fixed settlement provisions.
Recently Issued Accounting Pronouncements	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entitiy’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period. If substantial doubt exists, additional disclosure is required. This new standard will be effective for the Company for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. Adoption of this pronouncement is not expected to have a material impact on its consolidated financial statements.
	The FASB has issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The Company has not yet determined the effect of the adoption of this standard and its impact on the Company's consolidated financial position and results of operations.
	The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supercedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The Company has not yet determined the effect of the adoption of this standard and its impact on the Company's consolidated financial position and results of operations.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies Tables
Schedule of Potentially Dilutive Securities	Potentially dilutive securities are excluded from the computation of diluted net earnings (loss) per share if their inclusion would be anti-dilutive and consist of the following:
		December 31,
		2014		2013
	Options		3,944,557		2,543,150
	Warrants		9,339,044		2,342,846
	Series B Convertible Preferred Stock		5,146,902		3,472,953
	Total potentially dilutive shares		18,430,503		8,358,949

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property And Equipment Tables
Summary of property and equipment	Property and equipment consist of the following:
		December 31,						Estimated
		2014			2013			Useful Life
	Computer Software	$	230,299		$	230,299		5 years
	Equipment		544,108			544,108		15 years
	Office Furniture and Equipment		95,754			95,754		7 years
	Computer Hardware		30,710			27,746		5 years
	Leasehold Improvements		303,318			303,318		(a)
	Total		1,204,189			1,201,225
	Less:  accumulated depreciation		(692,903	)		(576,591	)
	Property and Equipment, Net	$	511,286		$	624,634
	(a)    Lesser of useful life or initial term of lease

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Expenses And Other Current Liabilities Tables
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities consisted of the following:
			December 31,
			2014		2013
	Deferred Rent		$	36,053	$	46,254
	Advertising			109,930		75,000
	Salaries and Benefits			82,222		132,048
	Customer Payables			635		39,618
	Dividend Payable			298,918		279,380
	Accrued Interest			48,868		45,616
	Accrued Rent			46,604		-
	Other			57,276		3,136
		Total	$	680,506	$	621,052

Equipment_Lease_Payable_Tables

Equipment Lease Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Equipment Lease Payable Tables
Summary of future minimum lease payments	Future minimum lease payments, by year and in the aggregate, under equipment leases, which includes capital leases, as of December 31, 2014, are as follows:
	For year ending December 31,	Lease Payments
	2015	$	76,086
	2016		48,696
	Total	$	124,782
	Less:  Amount representing interest		(14,538	)
	Present value of future lease payments	$	110,244
	Less:  Current portion		(64,101	)
	Long term portion	$	46,143

Stockholders_Deficiency_Tables

Stockholders' Deficiency (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders Deficiency Tables
Schedule of Stock Options Granted	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			For Year Ended
			December 31,
			2014		2013
	Risk free interest rate		0.97% to 2.29%		1.13% to 2.03%
	Dividend yield		0.00%		0.00%
	Expected volatility		190% to 191.0%		162.0% to 175.0%
	Expected life in years		3.0 to 10.0		5.5 to 6.0
Summary of Stock Option Activity	A summary of the stock option activity during the years ended December 31, 2014 and 2013 is presented below:
										Weighted
							Weighted			Average
							Average			Remaining	Aggregate
			Number of				Exercise			Life	Intrinsic
			Options				Price			In Years	Value
	Outstanding, January 1, 2013			2,183,899			$	2.76
	Granted			935,500				0.91
	Exercised			-				-
	Forfeited			(576,249	)			3.96
	Outstanding, December 31, 2013			2,543,150			$	2.37
	Outstanding, January 1, 2014			2,543,150			$	2.37
	Granted			1,937,857				0.13
	Exercised			-				-
	Forfeited			(536,450	)			2.37
	Outstanding, December 31, 2014			3,944,557			$	1.27		7.4	$                -
	Exercisable, December 31, 2014			3,135,876			$	1.11		8.0	$                -
Summary of Stock Option Outstanding and Exercisable	The following table presents information related to stock options at December 31, 2014:
					Options Outstanding							Options Exercisable
					Weighted							Weighted		Weighted
	Range of				Average				Outstanding			Average		Average		Exercisable
	Exercise				Exercise				Number of			Exercise		Remaining Life		Number of
	Price				Price				Options			Price		In Years		Options
	$	0.12 - $2.20			$	0.36				2,870,807		$	0.26		9.2		2,339,126
	$	2.21 - $3.80				3.23				757,750			2.95		3		507,750
	$	3.81 - $6.99				4.88				316,000			4.73		7		289,000
	$	0.12 - $6.99			$	1.27				3,944,557		$	1.11		8		3,135,876
Schedule of Stock Warrants Granted	In applying the Black-Scholes option pricing model to stock warrants granted, the Company used the following weighted average assumptions:
	Grants
			For Year Ended
			December 31,
			2014		2013
	Risk free interest rate		1.52% to 2.52%		0.74% to 2.84%
	Dividend yield		0.00%		0.00%
	Expected volatility		171% to 192%		146% to 173.0%
	Expected life in years		5.0 to 8.5		5.0 to 9.5
Summary of Stock Warrant Activity	A summary of the stock warrant activity during the years ended December 31, 2014 and 2013, respectively, is presented below:
										Weighted
							Weighted			Average
							Average			Remaining
			Number of				Exercise			Life	Intrinsic
			Warrants				Price			In Years	Value
	Outstanding, January 1, 2013			592,846			$	3.01
	Granted			14,255,023			$	0.28
	Exercised			(12,505,023	)		$	0.28
	Forfeited			-			$	-
	Outstanding, January 1, 2014			2,342,846			$	0.94
	Granted			6,996,198			$	0.28
	Exercised			-				-
	Forfeited			-				-
	Outstanding, December 31, 2014			9,339,044			$	0.45		4.2	$                -
	Exercisable, December 31, 2014			9,079,044			$	0.38		4.3	$                -
Summary of Stock Warrants Outstanding and Exercisable	The following table presents information related to stock warrants at December 31, 2014:
					Warrants Outstanding							Warrants Exercisable
					Weighted							Weighted		Weighted
	Range of				Average				Outstanding			Average		Average		Exercisable
	Exercise				Exercise				Number of			Exercise		Remaining Life		Number of
	Price				Price				Warrants			Price		In Years		Warrants
	$	0.15 - $0.35			$	0.28				8,746,198		$	0.28		4.4		8,746,198
	$	0.36 - $3.00				2.91				562,846			2.91		1.7		312,846
	$	3.01 - $4.95				4.95				30,000			4.95		2.8		20,000
	$	0.15 - $4.05				0.45				9,339,044		$	0.38		4.3		9,079,044

Commitments_and_Contingent_Lia1

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingent Liabilities Tables
Summary of future minimum payments under operating leases	Future minimum payments, by year and in the aggregate, under operating leases as of December 31, 2014 are as follows:
	For year ending December 31,	Amount
	2015	$	140,052
	2016		155,700
	2017		12,000
	2018		5,000
	Total future minimum lease payments	$	312,752

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes Tables
Summary of income tax provision (benefit)	The income tax provision (benefit) for the years ended December 31, 2014 and 2013 was as follows:
		For The Year Ended
		December 31,
		2014			2013
	Federal:
	Current	$	-		$	-
	Deferred		(387,752	)		(625,702	)
	State and local:
	Current		-			-
	Deferred		(161,244	)		(36,806	)
			(548,996	)		(662,508	)
	Change in valuation allowance		548,996			662,508
	Income tax provision (benefit)	$	-		$	-
Summary of significant portions of the deferred tax assets and liabilities	The effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows:
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	5,315,823		$	4,966,018
	Stock-based compensation		722,782			466,078
	Inventory reserves		6,090			10,949
	Allowance for bad debt		17,948			89,899
	Deferred Rent		14,108			-
	Contingent Liability		1,910			-
	Charitable contribution carryforwards		5,772			5,630
	Accruals		31,007			27,352
	Total deferred tax assets		6,115,440			5,565,926
	Valuation allowance		(6,088,174	)		(5,539,178	)
	Deferred tax assets, net of valuation allowance		27,266			26,748
	Deferred tax liabilities:
	Property and equipment		(27,266	)		(26,748	)
	Net deferred tax assets	$	-		$	-
	Change in valuation allowance	$	548,996		$	666,508
Summary of tax expense (benefit) based on the statutory rate	For the years ended December 31, 2014 and 2013, the expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax expense (benefit) as follows:
		For The Year Ended
		December 31,
		2014			2013
	US federal statutory rate		(34.0	%)		(34.0	%)
	State tax rate, net of federal benefit		(4.0	%)		(2.0	%)
	Permanent differences
	- Stock based compensation		4.8	%		3.2	%
	- Debt extinquishment		0	%		18.3	%
	- Other		2.4	%		2.5	%
	Change in valuation allowance		30.8	%		12	%
	Income tax provision (benefit)		0	%		0	%

Going_Concern_and_Managements_1

Going Concern and Management's Liquidity Plans (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Going Concern And Managements Liquidity Plans Details Narrative
Working Capital Deficiency	$4,237,165
Accumulated deficit	30,212,865	28,130,668
Net Losses	1,783,279	5,489,892
Net Cash Used in Operating Activities	$875,769	$1,024,781

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details
Options	$3,944,557	$2,543,150
Warrants	9,339,044	2,342,846
Series B Convertible Preferred Stock	5,146,902	3,472,953
Total potentially dilutive shares	$18,430,503	$8,358,949

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details Narrative
Cash equivalents	$0	$0
Allowance for doubtful accounts	47,233	250,828
Website development costs	114,616	98,423
Estimated future amortization expense related to website development costs in 2015	71,013
Estimated future amortization expense related to website development costs in 2016	56,370
Estimated future amortization expense related to website development costs in 2017	15,158
Amortization expense	55,855	14,643
Unamortized website development costs	142,541	83,780
Shipping and handling costs	511,636	775,083
Amounts recognized in revenues	162,221	254,067
Interest or penalties	0	0
Advertising expense	$103,536	$1,867

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property and Equipment, Gross	$1,204,189	$1,201,225
Less: accumulated depreciation	-692,903	-576,591
Property and Equipment, Net	511,286	624,634
Computer Software [Member]
Estimates Useful Life	5 years
Property and Equipment, Gross	230,299	230,299
Equipment [Member]
Estimates Useful Life	15 years
Property and Equipment, Gross	544,108	544,108
Office Furniture and Equipment [Member]
Estimates Useful Life	7 years
Property and Equipment, Gross	95,754	95,754
Computer Hardware [Member]
Estimates Useful Life	5 years
Property and Equipment, Gross	30,710	27,746
Leasehold Improvements [Member]
Property and Equipment, Gross	$303,318	$303,318

Property_and_Equipment_Details1

Property and Equipment (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property And Equipment Details Narrative
Depreciation expense	$116,312	$143,387

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses And Other Current Liabilities Details
Deferred rent	$36,053	$46,254
Advertising	109,930	75,000
Salaries and benefits	82,222	132,048
Customer payables	635	39,618
Dividends payable	298,918	279,380
Accrued interest	48,868	45,616
Accrued Rent	46,604
Other	57,276	3,136
Total	$680,506	$621,052

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt discount unamortized		$44,363
Interest rate of Senior Note	7.50%
Aggregate number of warrants issued	1,125,000
Warrants issued ixercise price	$0.35	$0.35
Warrants issued	225,000	900,000
Fair value related to warrants	402,500
Fair value related to warrants as debt discount	36,000	366,500
Debt discount as interest expense amortized	229,231	130,235
Debt discount as interest expense unamortized	43,034	236,265
Principal payments made to related party	5,000	4,000
Interest expense	3,252	1,366
Borrowing amount of loan	150,000	600,000
Total borrowing amount of loan	750,000
Lender [Member]
Interest rate of Senior Note	3.25%
Warrant Related Note [Member]
Debt discount unamortized	15,333	33,733
Amortization of the debt discount as interest expense	$18,400	$3,067

Equipment_Lease_Payable_Detail

Equipment Lease Payable (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Equipment Lease Payable Details
2015	$76,086
2016	48,696
Total	124,782
Less: amount representing interest	-14,538
Present value of future lease payments	110,244
Less: Current portion	-64,101	-56,323
Long term portion	$46,143	$109,964

Equipment_Lease_Payable_Detail1

Equipment Lease Payable (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Equipment Lease Payable Details Narrative
Gross Book value of equiment	$305,641
Net Book value of equiment	240,720
Depreciation of assets held under capital leases	$20,377	$20,377

Stockholders_Deficiency_Detail

Stockholders' Deficiency (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Dividend yield	0.00%	0.00%
Minimum [Member]
Risk free interest rate	0.97%	1.13%
Expected volatility	190.00%	162.00%
Expected life in years	3 years	5 years 6 months
Maximum [Member]
Risk free interest rate	2.29%	2.03%
Expected volatility	191.00%	175.00%
Expected life in years	10 years	6 years

Stockholders_Deficiency_Detail1

Stockholders' Deficiency (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Number of options, outstanding
Outstanding, beginning of period (in shares)	2,543,150	2,183,899
Granted	1,937,857	935,500
Exercised
Forfeited	-536,450	-576,249
Outstanding, end of period (in shares)	3,944,557	2,543,150
Exercisable, December 31, 2014	3,135,876
Options, weighted average exercise price
Outstanding, beginning of period (in dollars per share)	$2.37	$2.76
Granted	$0.13	$0.91
Exercised
Forfeited	$2.37	$3.96
Outstanding, end of period (in dollars per share)	$1.27	$2.37
Exercisable, December 31, 2014	$1.11
Weighted Average Remaining Life In Years
Weighted Average Remaining Life (in years) Outstanding	7 years 4 months 24 days
Weighted Average Remaining Life (in years) Exercisable	8 years
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding
Aggregate Intrinsic Value Exercisable

Stockholders_Deficiency_Detail2

Stockholders' Deficiency (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted Average Exercise Price Outstanding	$1.27	$2.37	$2.76
Number Outstanding	3,944,557	2,543,150	2,183,899
Number Exercisable	3,135,876
$0.12 - $2.20
Weighted Average Exercise Price Outstanding	$0.36
Number Outstanding	2,870,807
Weighted Average Exercise Price Exercisable	$0.26
Weighted Average Remaining Years of Contractual Life	9 years 2 months 12 days
Number Exercisable	2,339,126
$2.21 - $3.80
Weighted Average Exercise Price Outstanding	$3.23
Number Outstanding	757,750
Weighted Average Exercise Price Exercisable	$2.95
Weighted Average Remaining Years of Contractual Life	3 years
Number Exercisable	507,750
$3.81 - $6.99
Weighted Average Exercise Price Outstanding	$4.88
Number Outstanding	316,000
Weighted Average Exercise Price Exercisable	$4.73
Weighted Average Remaining Years of Contractual Life	7 years
Number Exercisable	289,000
$0.12 - $6.69
Weighted Average Exercise Price Outstanding	$1.27
Number Outstanding	3,944,557
Weighted Average Exercise Price Exercisable	$1.11
Weighted Average Remaining Years of Contractual Life	8 years
Number Exercisable	3,135,876

Stockholders_Deficiency_Detail3

Stockholders' Deficiency (Details 3)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Dividend yield	0.00%	0.00%
Warrant [Member]
Dividend yield	0.00%	0.00%
Minimum [Member]
Risk free interest rate	0.97%	1.13%
Expected volatility	190.00%	162.00%
Expected life in years	3 years	5 years 6 months
Minimum [Member] | Warrant [Member]
Risk free interest rate	1.52%	0.74%
Expected volatility	171.00%	146.00%
Expected life in years	5 years	5 years
Maximum [Member]
Risk free interest rate	2.29%	2.03%
Expected volatility	191.00%	175.00%
Expected life in years	10 years	6 years
Maximum [Member] | Warrant [Member]
Risk free interest rate	2.52%	2.84%
Expected volatility	192.00%	173.00%
Expected life in years	8 years 6 months	9 years 6 months

Stockholders_Deficiency_Detail4

Stockholders' Deficiency (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Number of warrants, outstanding
Outstanding, beginning of period (in shares)	2,543,150	2,183,899
Granted	1,937,857	935,500
Exercised
Forfeited	-536,450	-576,249
Outstanding, end of period (in shares)	3,944,557	2,543,150
Exercisable, December 31, 2014	3,135,876
Weighted average exercise price
Outstanding, beginning of period (in dollars per share)	$2.37	$2.76
Granted	$0.13	$0.91
Exercised
Forfeited	$2.37	$3.96
Outstanding, end of period (in dollars per share)	$1.27	$2.37
Exercisable, December 31, 2014	$1.11
Weighted Average Remaining Life In Years
Weighted Average Remaining Life (in years) Outstanding	7 years 4 months 24 days
Weighted Average Remaining Life (in years) Exercisable	8 years
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding
Aggregate Intrinsic Value Exercisable
Warrant [Member]
Number of warrants, outstanding
Outstanding, beginning of period (in shares)	2,342,846	592,846
Granted	6,996,198	14,255,023
Exercised		-12,505,023
Forfeited
Outstanding, end of period (in shares)	9,339,044	2,342,846
Exercisable, December 31, 2014	9,079,044
Weighted average exercise price
Outstanding, beginning of period (in dollars per share)	$0.94	$3.01
Granted	$0.28	$0.28
Exercised		$0.28
Forfeited
Outstanding, end of period (in dollars per share)	$0.45	$0.94
Exercisable, December 31, 2014	$0.38	$0.66
Weighted Average Remaining Life In Years
Weighted Average Remaining Life (in years) Outstanding	4 years 2 months 12 days
Weighted Average Remaining Life (in years) Exercisable	4 years 3 months 18 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding
Aggregate Intrinsic Value Exercisable

Stockholders_Deficiency_Detail5

Stockholders' Deficiency (Details 5) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted Average Exercise Price Outstanding	$1.27	$2.37	$2.76
Number Outstanding	3,944,557	2,543,150	2,183,899
Number Exercisable	3,135,876
Warrant [Member]
Weighted Average Exercise Price Outstanding	$0.45	$0.94	$3.01
Number Outstanding	9,339,044	2,342,846	592,846
Number Exercisable	9,079,044
$0.15 - $0.35 | Warrant [Member]
Weighted Average Exercise Price Outstanding	$0.28
Number Outstanding	8,746,198
Weighted Average Exercise Price Exercisable	$0.28
Weighted Average Remaining Years of Contractual Life	4 years 4 months 24 days
Number Exercisable	8,746,198
$0.36 - $3.00 | Warrant [Member]
Weighted Average Exercise Price Outstanding	$2.91
Number Outstanding	562,846
Weighted Average Exercise Price Exercisable	$2.91
Weighted Average Remaining Years of Contractual Life	1 year 8 months 12 days
Number Exercisable	312,846
$3.01 - $4.95 | Warrant [Member]
Weighted Average Exercise Price Outstanding	$4.95
Number Outstanding	30,000
Weighted Average Exercise Price Exercisable	$4.95
Weighted Average Remaining Years of Contractual Life	2 years 9 months 18 days
Number Exercisable	20,000
$0.15 - $4.05 | Warrant [Member]
Weighted Average Exercise Price Outstanding	$0.45
Number Outstanding	9,339,044
Weighted Average Exercise Price Exercisable	$0.38
Weighted Average Remaining Years of Contractual Life	4 years 3 months 18 days
Number Exercisable	9,079,044

Stockholders_Deficiency_Detail6

Stockholders' Deficiency (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Proceeds related to private placement offering, value		$3,501,975
Proceeds related to private placement offering, units		3,501,975
Proceeds related to private placement offering, per unit		$1
Amount received from officer		500,000
Amount classified as restricted cash		850,002
Aggregate intrinsic value of exercised	0
Weighted Average annual rate of option forfeiture	4.00%	4.00%
Weighted average fair value of the stock granted	$0.16	$0.91
Selling, general and administrative expenses	5,370,727	7,554,954
Stock-based compensation expense related to stock options/ warrants, unamortized	1,135,635
Stock-based compensation expense related to stock options/warrants, to be amortized	244,066
Weighted average remaining period	1 year 1 month 6 days
Common Stock to three holders of warrants		1,465,578
Common Stock to three holders of warrants, exercised		2,353,744
Common Stock to several holders of warrants		10,342,931
Common Stock to several holders of warrants, exercised		12,505,023
Stock-based compensation expense related for consultant warrants	-722	-17,718
Recorded salary expense	116,666	350,000
Stock-based compensation expense related to stock options/ warrants	698,015	558,286
Warrant [Member]
Aggregate intrinsic value of exercised		16,983,736
Weighted average fair value of the stock granted	$0.20	$1.34
Selling, general and administrative expenses	722
Stock-based compensation expense related to stock options/ warrants, unamortized	577,523
Stock-based compensation expense related to stock options/warrants, to be amortized	683
Weighted average remaining period	9 months 18 days
Grant date value performance based warrant, unamortized	576,840
Stock-based compensation expense related to stock options/ warrants	132,503	490,420
Series B Preferred Stock [Member]
Share issued upon conversion	11.39	8.22
Beneficial Conversion Feature Related to Incremental Shares	2,887,507
Beneficial Conversion Feature Related to Incremental Value	7,288,068	1,532,722
Accrued contractual dividends	298,918	279,380
Series A Preferred Stock [Member]
Series A Preferred Stock are available to be issued		44,443
Stock Option [Member]
Fair value of shares issued as compensation	10,646
Private Placement [Member]
Gross proceeds received	1,653,000	3,501,975
Net of expenses recorded	$115,245
Total Units sold	11,020,003	3,501,975
Total Units sold, per share	$0.15	$1

Commitments_and_Contingent_Lia2

Commitments and Contingent Liabilities (Details 1) (USD $)	Dec. 31, 2014
Commitments And Contingent Liabilities Details 1
2015	$140,052
2016	155,700
2017	12,000
2018	5,000
Total future minimum lease payments	$312,752

Commitments_and_Contingent_Lia3

Commitments and Contingent Liabilities (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments And Contingent Liabilities Details Narrative
Deferred rent payable	$36,053	$46,254
Lease payments	46,604
Rent Expense	250,576	174,661
Unpaid balance	$135,000

Concentrations_Details_Narrati

Concentrations (Details Narrative)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Vendor 1 [Member]
Concentration Inventory Purchases Percentage	68.00%	61.00%
Concentration Accounts Payable Percentage	36.00%	26.00%
Vendor 2 [Member]
Concentration Inventory Purchases Percentage	14.00%	14.00%

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions Details Narrative
Consulting and other expenses	$21,110
Director earned		12,000
Estimated the value of collateral	2,143	9,001
Recorded insurance premium expense	$24,329

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Federal:
Current
Deferred	-387,752	-625,702
State and local:
Current
Deferred	-161,244	-36,806
Income tax total	-548,996	-662,508
Change in valuation allowance	548,996	662,508
Income tax provision (benefit)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards	$5,315,823	$4,966,018
Stock-based compensation	722,782	466,078
Inventory reserves	6,090	10,949
Allowance for bad debt	17,948	89,899
Deferred Rent	14,108
Contingent Liability	1,910
Charitable contribution carryforwards	5,772	5,630
Accruals	31,007	27,352
Total deferred tax assets	6,115,440	5,565,926
Valuation allowance	-6,088,174	-5,539,178
Deferred tax assets, net of valuation allowance	27,266	26,748
Deferred tax liabilities:
Property and equipment	-27,266	-26,748
Net deferred tax assets
Change in valuation allowance	$548,996	$666,508

Income_Taxes_Details_2

Income Taxes (Details 2)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Details 2
US federal statutory rate	-34.00%	-34.00%
State tax rate, net of federal benefit	-4.00%	-2.00%
Permanent differences
Stock based compensation	4.80%	3.20%
Debt extinquishment	0.00%	18.30%
Other	2.40%	2.50%
Change in valuation allowance	30.80%	12.00%
Income tax provision (benefit)	0.00%	0.00%

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Details Narrative
Federal net operating loss carry forwards	$14,736,276	$13,770,000
State net operating loss carry forwards	$7,637,237	$3,585,000
Federal net operating loss carry forwards expiry period	2027 to 2034
State net operating loss carry forwards expiry period	2031